Home › Funds › Affinity Asset Advisors, LLC › COAG
Affinity Asset Advisors, LLC position in COAG
HEMAB THERAPEUTICS HLDGS INC · Health Care
Affinity Asset Advisors, LLC reported holding 420,000 shares of COAG (HEMAB THERAPEUTICS HLDGS INC) in its Q3 2026 13F filing — a position valued at US$13.0M, representing 0.60% of its reported portfolio and ranking #41 among its reported holdings. Affinity Asset Advisors, LLC has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's COAG position evolved
Affinity Asset Advisors, LLC first disclosed a stake in COAG in Q2 2026 at 138,030 shares (US$5.1M). The position peaked in Q3 2026 at 420,000 shares, worth US$13.0M. Across 2 filings, Affinity Asset Advisors, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 420,000 shares valued at US$13.0M — an increase of 281,970 shares quarter over quarter.. Notable position changes include a 204% increase in Q3 2026 (shares rose 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 138.03K | $5.07M | New |
| Q3 2026 | 420.00K | $12.95M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About COAG and 13F data
COAG (HEMAB THERAPEUTICS HLDGS INC) is a Health Care company. 80 other funds we track also report a position in COAG — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$286.8M), Novo Holdings A/S (US$153.6M), Deep Track Capital, LP (US$132.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding COAG
- RA CAPITAL MANAGEMENT, L.P. 7.81M sh · $286.81M · Q2 2026
- Novo Holdings A/S 4.18M sh · $153.55M · Q2 2026
- Deep Track Capital, LP 3.60M sh · $132.30M · Q2 2026
- Siren, L.L.C. 2.37M sh · $72.97M · Q3 2026
- Avoro Capital Advisors LLC 1.93M sh · $70.71M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 1.65M sh · $60.60M · Q2 2026
- Rock Springs Capital Management LP 575.43K sh · $21.14M · Q2 2026
- Opaleye Management Inc. 47.65K sh · $1.75M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held COAG?
Affinity Asset Advisors, LLC has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Affinity Asset Advisors, LLC's current position in COAG?
As of Q3 2026, Affinity Asset Advisors, LLC holds 420.00K shares of COAG (HEMAB THERAPEUTICS HLDGS INC), valued at $12.95M, representing 0.60% of its reported portfolio and ranking #41.
Has Affinity Asset Advisors, LLC been buying or selling COAG?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in COAG. The position peaked in Q3 2026 at 420.00K shares.
Which other funds hold COAG?
Other major institutional holders of COAG include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, Deep Track Capital, LP, among 80 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.